0
No hay productos en el carro de la compra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > Beads > Spike protein > MBS-K030

SARS-CoV-2 Spike Trimer (B.1.351) Coupled Magnetic Beads

Order Now

ItemsSize (2mg)Size(5mg X 2)
Particle size2 μm2 μm
Physical appearancePowder mixturePowder mixture
Amount of Coupled Protein≈294 pmol (41 μg) SARS-CoV-2 Spike Trimer (B.1.351)/mg beads≈294 pmol (41 μg) SARS-CoV-2 Spike Trimer (B.1.351)/mg beads
Binding Capacity>126 pmol (19 μg) Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody/mg beads>126 pmol (19 μg) Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody/mg beads
FormulationPBS, pH7.4, with 10% TrehalosePBS, pH7.4, with 10% Trehalose
Reconstitution2 mL sterile deionized water (1 mg beads/mL)5 mL sterile deionized water (1 mg beads/mL)
  • Background
    The SARS-CoV-2 Spike Trimer (B.1.351) Coupled Magnetic Beads is produced by coupling biotinylated SARS-CoV-2 spike trimer to streptavidin-conjugated magnetic beads. The spike proteins coupled to the beads contain 10 mutations (L18F, D80A, D215G, 242-244del, R246I, K417N, E484K, N501Y, D614G, A701V) identified in the South African variant (known as B.1.351 or 20C/501Y.V2). The pre-coupled beads are ready to use for capturing anti-SARS-CoV-2 antibody or ACE2 protein from your sample with high specificity.
  • Source
    SARS-CoV-2 Spike Trimer (B.1.351) Protein is expressed from human 293 cells (HEK293). It contains AA Val 16 - Pro 1213(Accession # QHD43416.1 (L18F, D80A, D215G, 242-244del, R246I, K417N, E484K, N501Y, D614G, A701V, R683A, R685A,F817P, A892P, A899P, A942P, K986P, V987P)).
  • Application
    This product is intended for immunocapture, biopanning and flow cytometry. This product is produced non-sterile.
  • Reconstitution

    See Certificate of Analysis (CoA) for detailed instruction.

  • Storage
    Upon receipt, please store the Beads at -20°C. The shelf life is 1 year at -20 °C.Please avoid more than 3 freeze-thaw cycles once reconstitution, immediate use after reconstitution is highly recommended.
  • Assay Principles
    Antibody Purification: 1. Resuspend the lyophilized beads by adding the buffer of choice. 2. Add analyte to the suspension, mix and incubate to enable specific binding of the beads and the target protein. 3. Magnetize beads, remove supernatant, and wash unbound protein fractions to capture target protein-bound beads. 4. Wash, magnetize the beads and collect purified target protein for use in downstream applications.

    The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications.

  • Formulation

    Please contact us for detailed information.

    Contact us for customized product form or formulation.

Typical Data
 Spike protein TYPICAL DATA

Immobilized 41μg S protein trimer/1mg beads can bind the Anti-S1 Antibody with an EC50 of 0.5951μg/mL.

 Spike protein TYPICAL DATA

Accelerated stability test. After placing the lyophilized beads at 37°C for 7 days, binding activity between the SARS-CoV-2 Spike Trimer (B.1.351) Coupled Magnetic Beads (Cat.No. MBS-K030) and anti-SARS-CoV-2 Spike S1 antibody showed little deviation from the unaccelerated sample(%RSD<5%). Data were measured on day 0, 3, 7 respectively.

 Spike protein TYPICAL DATA

Freeze-thaw stability test. After different freeze-thaw cycles, binding activity between SARS-CoV-2 Spike Trimer (B.1.351) Coupled Magnetic Beads (Cat.No. MBS-K030) and anti-SARS-CoV-2 Spike S1 antibody showed little deviation from the unfree-thaw sample (%RSD<5%). Three freeze-thaw cycles were performed.

  • Clinical and Translational Updates

Comments (0)


ETA de productos en stock: 2 días laborables

Price(EUR) : €810.00

Price(EUR) : €2530.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:1 Details
  • Number of Drugs in Clinical Trials:1 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Email
Correo electrónico
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Dejar un mensaje